Self Efficacy, Walking Ability, Gait Speed and Physical Activity in People With Chronic Lung Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01583595|
Recruitment Status : Completed
First Posted : April 24, 2012
Last Update Posted : April 4, 2013
Most patients with chronic lung disease underestimate their actual walking ability due to low confidence. To better understand the relationships between lung function, self-efficacy for walking (confidence in ability to walk a defined distance), actual walking ability for the same distance gait speed and physical activity level-PAL- (total energy expenditure/resting metabolic rate).
Quality of life, self efficacy for activity questionnaires, physical activity level measurement, 4-meter gait speed and 6-minute walk distance will be measured.
|Condition or disease|
|Chronic Lung Disease Self-efficacy|
|Study Type :||Observational|
|Actual Enrollment :||70 participants|
|Official Title:||Determining the Relationships Between Self-efficacy for Walking Ability, Gate Speed and Physical Activity in Patients With Chronic Lung Disease|
|Study Start Date :||December 2011|
|Actual Primary Completion Date :||July 2012|
|Actual Study Completion Date :||July 2012|
- Analyze associations between self-efficacy for walking, gait speed, physical activity level and perceptions of symptoms in patient with chronic lung disease (COPD and Pulmonary Fibrosis) [ Time Frame: Day of enrollment. ]Correlation , regression models and mediation analysis (self efficacy and physical activity) will be performed.
- Predictive utility of 4-meter gait speed for estimating physical activity level (PAL) as validated by gold standard activity monitor. [ Time Frame: 1 week ]Measure 4-meter gait speed during standardized 6 mintute walk test and compare to armband activity monitor results to determine predictive ability, if any, on PAL in people with chronic lung disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01583595
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Roberto P Benzo, M.D., MSc||Mayo Clinic|